{"id":63075,"date":"2026-06-12T14:38:12","date_gmt":"2026-06-12T18:38:12","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/fda-approves-astrazenecas-truqap-for-prostate-cancer-uk-sets-russian-fuel-ban-deadline-imf-reaches-deal-with-ukraine\/63075\/"},"modified":"2026-06-12T14:38:12","modified_gmt":"2026-06-12T18:38:12","slug":"fda-approves-astrazenecas-truqap-for-prostate-cancer-uk-sets-russian-fuel-ban-deadline-imf-reaches-deal-with-ukraine","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/fda-approves-astrazenecas-truqap-for-prostate-cancer-uk-sets-russian-fuel-ban-deadline-imf-reaches-deal-with-ukraine\/63075\/","title":{"rendered":"FDA Approves AstraZeneca\u2019s Truqap for Prostate Cancer; UK Sets Russian Fuel Ban Deadline; IMF Reaches Deal with Ukraine"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>)<\/strong> received <strong>FDA approval<\/strong> for <strong>Truqap<\/strong> (capivasertib) as the first targeted treatment for <strong>PTEN-deficient metastatic hormone-sensitive prostate cancer<\/strong>, reducing the risk of disease progression or death by <strong>19%<\/strong>.<\/li>\n<li>The <strong>UK Government<\/strong> confirmed a <strong>January 1, 2027<\/strong> end date for imports of <strong>Russian diesel and jet fuel<\/strong> refined in third countries, closing a major &quot;loophole&quot; in its sanctions regime.<\/li>\n<li>The <strong>IMF<\/strong> reached a staff-level agreement with <strong>Ukraine<\/strong> on the first review of its <strong>$8.1 billion<\/strong> loan program, clearing the path for a <strong>$690 million<\/strong> disbursement pending board approval.<\/li>\n<li><strong>Ukraine<\/strong> met all quantitative performance criteria for the review period, though it missed one structural benchmark, requiring a revised reform timeline to maintain program momentum.<\/li>\n<\/ul>\n<h2>AstraZeneca Secures Landmark FDA Approval for Truqap<\/h2>\n<p>AstraZeneca (<a href=\"\/stock\/AZN\">AZN<\/a>) announced on Friday that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has approved <strong>Truqap<\/strong> (capivasertib) in combination with abiraterone and prednisone. This regulatory milestone establishes Truqap as the <strong>first and only targeted therapy<\/strong> specifically for adult patients with <strong>PTEN-deficient<\/strong> metastatic hormone-sensitive prostate cancer (mHSPC).<\/p>\n<p>The approval is based on the <strong>Phase III CAPItello-281<\/strong> trial, which demonstrated that the combination therapy achieved a median <strong>radiographic progression-free survival (rPFS) of 33.2 months<\/strong>, compared to 25.7 months for the control group. <em>PTEN deficiency<\/em>, which occurs in approximately <strong>25%<\/strong> of mHSPC cases, is typically associated with a poorer prognosis and faster disease progression.<\/p>\n<h2>UK Sets Final Deadline for Russian Refined Fuel Imports<\/h2>\n<p>The <strong>UK Government<\/strong> has officially set <strong>January 1, 2027<\/strong>, as the expiration date for the temporary license allowing the import of <strong>Russian-origin diesel and jet fuel<\/strong> processed in third countries. This move follows a new ban introduced on May 20, 2026, which initially included exemptions to maintain market stability and protect domestic supply chains.<\/p>\n<p>The <strong>Department for Business and Trade<\/strong> stated the timeline is designed to maximize pressure on the Russian economy while ensuring a smooth transition for UK businesses. Officials will continue to review the license every two weeks, with the intention to lift it sooner if market conditions allow. <em>Energy analysts<\/em> suggest the move aims to eliminate the &quot;refining loophole&quot; that has allowed Russian crude to enter Western markets via third-party refineries.<\/p>\n<h2>IMF and Ukraine Reach Agreement on $8.1 Billion Loan Review<\/h2>\n<p>The <strong>International Monetary Fund (IMF)<\/strong> and Ukrainian authorities have reached a staff-level agreement on the first review of the country\u2019s <strong>$8.1 billion Extended Fund Facility (EFF)<\/strong>. Upon approval by the IMF Executive Board, expected next month, Ukraine will gain access to approximately <strong>$690 million<\/strong> (SDR 503 million), bringing total disbursements under the current program to <strong>$2.2 billion<\/strong>.<\/p>\n<p>The IMF noted that Ukraine met all end-March quantitative performance criteria and indicative targets despite the ongoing conflict. However, because one structural benchmark was missed and two others were delayed, the agreement includes a <strong>revised timeline for reforms<\/strong> and additional policy commitments. The funds are earmarked to bolster <strong>macro-financial stability<\/strong> and support priority government expenditures as the country manages a total financing gap estimated at <strong>$136.5 billion<\/strong> through 2029.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways AstraZeneca (AZN) received FDA approval for Truqap (capivasertib) as the first targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[3403,5030,5042,5213,5833,7765,8715,15436],"class_list":["post-63075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-imf","tag-energy","tag-ukraine","tag-sanctions","tag-fda","tag-astrazeneca-azn-stock-azn","tag-oncology","tag-eff"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=63075"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63075\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=63075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=63075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=63075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}